PharmaCyte Net Income From Continuing Ops from 2010 to 2026
| PMCB Stock | USD 0.82 0.03 3.53% |
Net Income From Continuing Ops | First Reported 2017-01-31 | Previous Quarter -8.4 M | Current Value -7.4 M | Quarterly Volatility 5 M |
Check PharmaCyte Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PharmaCyte Biotech's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Other Operating Expenses of 5.4 M or EBITDA of 37 M, as well as many indicators such as Price To Sales Ratio of 3.3 K, Dividend Yield of 0.12 or PTB Ratio of 0.17. PharmaCyte financial statements analysis is a perfect complement when working with PharmaCyte Biotech Valuation or Volatility modules.
PharmaCyte | Net Income From Continuing Ops | Build AI portfolio with PharmaCyte Stock |
Analyzing PharmaCyte Biotech's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing PharmaCyte Biotech's current valuation and future prospects.
Latest PharmaCyte Biotech's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of PharmaCyte Biotech over the last few years. It is PharmaCyte Biotech's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PharmaCyte Biotech's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
PharmaCyte Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (3,118,774) | |
| Coefficient Of Variation | (653.24) | |
| Mean Deviation | 13,616,064 | |
| Median | (4,315,993) | |
| Standard Deviation | 20,372,976 | |
| Sample Variance | 415.1T | |
| Range | 64.3M | |
| R-Value | 0.89 | |
| Mean Square Error | 89.7T | |
| R-Squared | 0.80 | |
| Slope | 3,602,539 | |
| Total Sum of Squares | 6640.9T |
PharmaCyte Net Income From Continuing Ops History
About PharmaCyte Biotech Financial Statements
PharmaCyte Biotech stakeholders use historical fundamental indicators, such as PharmaCyte Biotech's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although PharmaCyte Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in PharmaCyte Biotech's assets and liabilities are reflected in the revenues and expenses on PharmaCyte Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PharmaCyte Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 35.3 M | 37 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out the analysis of PharmaCyte Biotech Correlation against competitors. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. Anticipated expansion of PharmaCyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PharmaCyte Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding PharmaCyte Biotech requires distinguishing between market price and book value, where the latter reflects PharmaCyte's accounting equity. The concept of intrinsic value—what PharmaCyte Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push PharmaCyte Biotech's price substantially above or below its fundamental value.
It's important to distinguish between PharmaCyte Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PharmaCyte Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, PharmaCyte Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.